 |
市場調查報告書
商品編碼
1535851
麴菌病治療市場- 依類型（急性、慢性麴菌病）、藥物類別（抗黴菌藥物[唑類、棘白菌素類、多烯類]、皮質類固醇[潑尼松龍、潑尼松]）、藥物形式、配銷通路- 全球預測 (2024 - 2032)Aspergillosis Treatment Market - By Type (Acute, Chronic Aspergillosis), Drug Class (Antifungal Drugs [Azoles, Echinocandins, Polyenes], Corticosteroids [Prednisolone, Prednisone]), Drug Form, Distribution Channel - Global Forecast (2024 - 2032) |
||||||
由於免疫功能低下個體（如接受化療、器官移植或愛滋病毒/愛滋病感染者）曲霉菌感染增加，預計 2024 年至 2032 年曲霉病治療市場複合年成長率將達到 4.3%。據 CDC 稱，大約 1-2% 的器官移植受者患有曲霉菌病。此外，氣喘和慢性阻塞性肺病等呼吸系統疾病的盛行率不斷上升，分別影響超過 2,500 萬和 1,600 萬美國人。由於免疫系統減弱，人口老化更容易受到感染，這進一步增加了對麴菌病治療的需求。
新抗真菌藥物的開發和診斷技術的改進提高了治療效果和準確性。對真菌感染研究的認知和資助的提高導致了更好的治療方案和更強大的醫療基礎設施。不斷成長的醫療保健投資，特別是在新興經濟體，預計將進一步推動市場，確保更廣泛地獲得先進治療並改善患者的治療效果。
整個麴菌病治療產業根據類型、藥物類別、藥物劑型、配銷通路和地區進行分類。
由於皮質類固醇類藥物在控制與感染相關的發炎反應方面的有效性，它有望在 2032 年之前獲得巨大的關注。皮質類固醇，如潑尼松和甲基潑尼松龍，通常用於減少過敏性支氣管肺麴菌病 (ABPA) 和慢性肺麴菌病 (CPA) 患者的發炎和免疫反應。這些藥物有助於緩解喘息、氣喘和胸悶等症狀，顯著緩解患者的症狀。呼吸系統疾病盛行率的增加和麴菌病發生率的上升正在推動對皮質類固醇的需求。
到 2032 年，注射劑細分市場將佔據顯著的市場佔有率，因為它在藥物輸送和功效方面具有優勢。注射製劑因其能夠將高劑量的藥物直接輸送到血液中而受到青睞，從而確保更快、更有效地治療嚴重或全身性曲霉菌感染。這種給藥途徑對於患有嚴重真菌感染的患者或因胃腸道問題或吸收問題而無法耐受口服藥物的患者至關重要。人們越來越重視快速有效的治療方案，加上注射藥物配方的進步，正在推動該細分市場的成長。
受真菌感染高盛行率、先進的醫療基礎設施和大量研究投資的推動，到 2032 年，北美曲霉菌病治療市場規模將快速擴大。該地區完善的醫療保健系統和強大的醫學研究能力促進了創新治療方案的開發和採用。此外，慢性呼吸道疾病和免疫功能低下疾病的發生率不斷上升，導致對有效麴菌病治療的需求增加。旨在改善醫療保健效果的政府措施和資金進一步促進了整個地區的市場成長。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 曲霉菌病發生率上升
- 人們對真菌感染的認知不斷增強
- 新型抗真菌劑的開發
- 產業陷阱與挑戰
- 治療選擇有限
- 治療費用高
- 成長動力
- 成長潛力分析
- 監管環境
- 技術景觀
- 核心技術
- 鄰近技術
- 2023 年定價分析
- 按地區
- 按關鍵人物
- 未來市場趨勢
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按類型，2021 - 2032
- 主要趨勢
- 急性麴菌病
- 慢性麴菌病
第 6 章：市場估計與預測：按藥物類別，2021 - 2032 年
- 主要趨勢
- 抗真菌藥物
- 唑類
- 棘白菌素
- 多烯
- 烯丙胺
- 其他抗真菌藥物
- 皮質類固醇
- 潑尼松龍
- 強的松
- 甲基強的松龍
- 其他皮質類固醇
- 其他藥品類
第 7 章：市場估計與預測：按藥物劑型，2021 - 2032 年
- 主要趨勢
- 口服
- 平板電腦
- 膠囊
- 注射
- 藥膏
- 粉末
第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥局
- 網路藥局
第 9 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- Abbott Laboratories
- Astellas Pharma Inc.
- Astra Zeneca PLC
- Basilea Pharmaceutica Ltd.
- Bayer AG
- Endo International plc
- F2G
- GSK plc
- Johnson & Johnson
- Merck & Co., Inc.
- Mayne Pharma Group Limited
- Novartis AG
- PULMATRiX, Inc.
- Takeda Pharmaceutical Company Ltd.
- Viatris Inc.
Aspergillosis treatment market is anticipated to record 4.3% CAGR over 2024-2032, driven by a rise in Aspergillosis infections among immunocompromised individuals, such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. According to the CDC, about 1-2% of organ transplant recipients develop Aspergillosis. Additionally, there is increasing prevalence of respiratory conditions like asthma and COPD, which affect over 25 million and 16 million Americans respectively. The aging population, more susceptible to infections due to weakened immune systems, further boosts demand for Aspergillosis treatments.
The development of new antifungal agents and improved diagnostic techniques has enhanced treatment efficacy and accuracy. Increased awareness and funding for fungal infection research have led to better treatment protocols and stronger healthcare infrastructure. Growing healthcare investments, particularly in emerging economies, are expected to further drive the market, ensuring wider access to advanced treatments and improving patient outcomes.
The overall Aspergillosis treatment industry is classified based on type, drug class, drug form, distribution channel, and region.
The corticosteroids drug class segment is poised to gain substantial traction through 2032 due to its effectiveness in managing inflammatory responses associated with the infection. Corticosteroids, such as prednisone and methylprednisolone, are commonly used to reduce inflammation and immune responses in patients with allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA). These drugs help alleviate symptoms such as wheezing, shortness of breath, and chest tightness, providing significant relief to patients. The increasing prevalence of respiratory conditions and the rising incidence of Aspergillosis are driving the demand for corticosteroids.
The injections segment will hold a notable market share by 2032, owing to the advantages it offers in terms of drug delivery and efficacy. Injectable formulations are preferred for their ability to deliver high doses of medication directly into the bloodstream, ensuring faster and more effective treatment of severe or systemic Aspergillosis infections. This route of administration is crucial for patients with severe fungal infections or those who cannot tolerate oral medications due to gastrointestinal issues or absorption problems. The growing emphasis on rapid and effective treatment options, coupled with advancements in injectable drug formulations, is driving the segment growth.
North American Aspergillosis treatment market size will expand at a rapid pace through 2032, driven by high prevalence rate of fungal infections, advanced healthcare infrastructure, and substantial research investments. The region's well-established healthcare systems and significant medical research capabilities facilitate the development and adoption of innovative treatment options. Additionally, the rising incidence of chronic respiratory diseases and immunocompromised conditions contributes to the increased demand for effective Aspergillosis therapies. Government initiatives and funding aimed at improving healthcare outcomes further bolster market growth across the region.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360°synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising incidence of aspergillosis
- 3.2.1.2 Growing awareness of fungal infections
- 3.2.1.3 Development of new antifungal agents
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Limited treatment options
- 3.2.2.2 High treatment costs
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
- 3.7 Future market trends
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Acute aspergillosis
- 5.3 Chronic aspergillosis
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Antifungal drugs
- 6.2.1 Azoles
- 6.2.2 Echinocandins
- 6.2.3 Polyenes
- 6.2.4 Allylamines
- 6.2.5 Other antifungal drugs
- 6.3 Corticosteroids
- 6.3.1 Prednisolone
- 6.3.2 Prednisone
- 6.3.3 Methylprednisolone
- 6.3.4 Other corticosteroids
- 6.4 Other drug class
Chapter 7 Market Estimates and Forecast, By Drug Form, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.2.1 Tablets
- 7.2.2 Capsules
- 7.3 Injections
- 7.4 Ointments
- 7.5 Powders
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 Astellas Pharma Inc.
- 10.3 Astra Zeneca PLC
- 10.4 Basilea Pharmaceutica Ltd.
- 10.5 Bayer AG
- 10.6 Endo International plc
- 10.7 F2G
- 10.8 GSK plc
- 10.9 Johnson & Johnson
- 10.10 Merck & Co., Inc.
- 10.11 Mayne Pharma Group Limited
- 10.12 Novartis AG
- 10.13 PULMATRiX, Inc.
- 10.14 Takeda Pharmaceutical Company Ltd.
- 10.15 Viatris Inc.
